Home Menu Search

(missing name)

Dr Andrew Burgess began his research career at the Queensland Institute of Medical Research in 1998 where he graduated with first-class honours and received a University of Queensland PhD scholarship. During this period his research was focused on the characterisation and discovery of a new class of

Biography

Dr Andrew Burgess began his research career at the Queensland Institute of Medical Research in 1998 where he graduated with first-class honours and received a University of Queensland PhD scholarship. During this period his research was focused on the characterisation and discovery of a new class of chemotherapy agents called histone deacetylase inhibitors. At the time very little was known about these compounds, but Andrew’s research identified how these agents were able to specifically kill both actively dividing and non-dividing cancer cells, laying the foundation for their successful transition from the bench into the clinic.

Upon completion of his PhD in 2004, Andrew was awarded a prestigious National Health and Medical Research Council CJ Martin Post-doctoral fellowship, which he took up in Montpellier, France, where he continued to explore the basic mechanism controlling the cell division process. During this time Andrew helped identify and characterise a completely new, critical mitotic gene, which has fundamentally altered our understanding of cell division. This work was published in several of the worlds top journals including Science, PNAS, and EMBO J, and has collectively been cited >600 times since 2010.

At the beginning of 2012, Andrew returned to Sydney, Australia to establish his own research group at Garvan within The Kinghorn Cancer Centre, where he is expanding his research on cell division and cancer. Andrew is a member of Sydney Catalyst, Young Garvan, Sydney Computational Biologists Forum, a co-organiser of the Australian Cell Cycle community conference, and a national director of the Australian Society for Medical Research (ASMR, 2015). In addition, he actively engages with the public through social media via his successful science blog, Twitter and Facebook lab pages. 

Dr Andrew Burgess began his research career at the Queensland Institute of Medical Research in 1998 where he graduated with first-class honours and received a University of Queensland PhD scholarship. During this period his research was focused on the characterisation and discovery of a new class of chemotherapy agents called histone deacetylase inhibitors. At the time very little was known about these compounds, but Andrew’s research identified how these agents were able to specifically kill both actively dividing and non-dividing cancer cells, laying the foundation for their successful transition from the bench into the clinic.

Upon completion of his PhD in 2004, Andrew was awarded a prestigious National Health and Medical Research Council CJ Martin Post-doctoral fellowship, which he took up in Montpellier, France, where he continued to explore the basic mechanism controlling the cell division process. During this time Andrew helped identify and characterise a completely new, critical mitotic gene, which has fundamentally altered our understanding of cell division. This work was published in several of the worlds top journals including Science, PNAS, and EMBO J, and has collectively been cited >600 times since 2010.

At the beginning of 2012, Andrew returned to Sydney, Australia to establish his own research group at Garvan within The Kinghorn Cancer Centre, where he is expanding his research on cell division and cancer. Andrew is a member of Sydney Catalyst, Young Garvan, Sydney Computational Biologists Forum, a co-organiser of the Australian Cell Cycle community conference, and a national director of the Australian Society for Medical Research (ASMR, 2015). In addition, he actively engages with the public through social media via his successful science blog, Twitter and Facebook lab pages. 

Awards and Honours

2016 - Cancer Australia Project Grant #APP1100722 (CIE)
2015 - The Patricia Helen Guest Fellowship
2015 - NHMRC Project Grant #APP1081312 (CIE)
2012 - Cancer Institute NSW, Future Research Leader Grant
2011 - EMBO Conference Scholarship, Cancéropôle du Sud-Ouest France
2009 - Société de Biologie Cellulaire de France (SBCF) Travel Grant
2009 - Foundation Reçherche Médicale (FRM) Post Doctoral Fellowship
2007 - La Ligue Nationale Contre le Cancer Post Doctoral Fellowship
2005 - Australian Government NHMRC CJ Martin Biomedical Fellowship
2003 - Queensland Cancer Fund Overseas Travel Scholarship
2003 - University of Queensland Research Scholar Award
2000 - University of Queensland Postgraduate Research Scholarship (UQPRS)

Education

2004 - PhD, University of Queensland - Australia
1999 - BSc Honours 1st Class, University of Queensland - Australia
1998 - BSc University of Queensland - Australia

Selected Publications

  1. *Burgess, A., *Vuong, J., Rogers, S., Malumbres, M., and O’Donoghue, S. I. (2017) SnapShot: Phosphoregulation of Mitosis. Cell 169, 1358–1358.e1 *equal contribution [Link]
  2. Szczepny, A., et al., *Burgess, A., and *Watkins, D. N. (2017) The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer. Oncogene 23, 2314 *co-corresponding [Link]

  3. Haupt, S., Vijayakumaran, R., Panimaya, J., Burgess, A., Lim, E., and Haupt, Y. (2017) The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol 9, 53–61 [Link]

  4. Vennin, C., et al…Burgess, A., Cox, T. R., Morton, J. P., Pajic, M., and Timpson, P. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med 9, [Link]

  5. Rogers, S., Fey, D., McCloy, RA., Parker, BL., Mitchell, NJ., Payne, RJ., Daly, RJ., James, DE., Caldon, CE., Watkins, DN., Croucher, DR., Burgess, A (2016) PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. J Cell Sci 129 (7), 1340-1354 [Link]

  6. Rogers, S., McCloy, R., Watkins, D. N., and Burgess, A. (2016) Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. BioEssays 38 Suppl 1, S24–32 [Link]

  7. A. Burgess et al., (2016) Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology. 6, 661. [Link]
  8. McCloy, R., Parker, B. L., Rogers, S., Chaudhuri, R., Gayevskiy, V., Hoffman, N. J., Ali, N., Watkins, D. N., Daly, R., James, D. E., Lorca, T., Castro, A., and Burgess, A. (2015) Global phosphoproteomic mapping of early mitotic exit in human cells identifies novel substrate dephosphorylation motifs. Molecular & Cellular Proteomics. (I.F = 7.25) [Link]
  9. Burgess, A. (2015) Degrading Claspin away with Cdh1 and Cyclin A. Cell Cycle 14, 171–171 (I.F = 5.36) [Link]
  10. Rogers, S., Gloss, B. S., Lee, C. S., Sergio, C. M., Dinger, M. E., Musgrove, E. A., Burgess, A., and Caldon, C. E. (2015) Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Division 10, 1 (I.F = 2.63) [Link]
  11. McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A (2014): Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle, 13:1400–1412. (I.F = 5.36). [Link]
  12. Burgess A*, Rasouli M, Rogers S (2014): Stressing mitosis to death. Frontiers in Oncology. 4:1-4. (I.F = N/A). [Link]
  13. McCloy RA, Shelley EJ, Roberts CG, Boslem E, Biden TJ, Nicholson RI, Gee JM, Sutherland RL, Musgrove EA, Burgess A, and Butt A (2013) Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. Br. J. Cancer 109: 3034–3041 [Link]
  14. Caldon CE, Sergio CM, Burgess A, Deans AJ, Sutherland RL, Musgrove EA (2013): Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle, 12:606–617. (I.F = 5.36) [Link]
  15. Burgess A, Lorca T, Castro A (2012): Quantitative Live Imaging of Endogenous DNA Replication in Mammalian Cells. PLoS ONE, 7:e45726. (I.F = 4.54) [Link]
  16. Gharbi-Ayachi A, Labbé J-C, Burgess A, Vigneron S, Strub J-M, Brioudes E, Van-Dorsselaer A, Castro A, Lorca T (2010): The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science, 330:1673–1677. (IF= 31.8) [Link]
  17. Burgess A, Vigneron S, Brioudes E, Labbé J-C, Lorca T, Castro A (2010): Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci USA, 107:12564–12569. (IF=10.59) [Link]
More Garvan Publications